Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 24;2(2):280-284.
doi: 10.1002/jha2.190. eCollection 2021 May.

ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations

Judith S Hecker  1 , Adam Wahida  1   2 , Erik Hameister  3   4 , Aneta Filo  3 , Jürgen Ruland  3 , Florian Bassermann  1 , Martin Hildebrandt  3   5 , Mareike Verbeek  1 , Hendrik Poeck  1   6
Affiliations
Case Reports

ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations

Judith S Hecker et al. EJHaem. .

Abstract

Allogeneic hematopoietic stem cell transplantations (HSCTs) represent a curative strategy for treating hematologic malignancies yet bear dangerous and frequently life-threatening complications including the development of graft-versus-host disease. Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow. During the course of his disease, the patient underwent consecutive allogeneic HSCTs, during which he developed a clinical meaningful and hitherto unreported ABO subgroup incompatibility, leading to persistent hemolysis. Testing for ABO subgroups during donor selection, especially after consecutive allogeneic HSCTs, may therefore aid to prevent these complications.

Keywords: A1/A2 subtyping of blood group A; ABO incompatibility; allogeneic hematopoietic stem cell transplantation; hemolysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

FIGURE 1
FIGURE 1
Course of disease and hemolysis. (A) Therapy response including IgA time course in relation to both allogeneic HSCTs from initial diagnosis 2013 to patient death 2019. (B) Time course of hemolysis with clinical laboratory values showing the hemoglobin, haptoglobin, and lactate dehydrogenase levels in serum in relation to the therapeutic algorithm and blood transfusion setting Abbreviations: CR, complete response; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial response; PRBC, packed red blood cells; VGPR, very good partial response.
See this image and copyright information in PMC

References

    1. Mookerjee A, Gupta R, Jasrotia S, Sahoo R, Kumar R, Thulkar S, et al. Bortezomib, lenalidomide and low‐dose dexamethasone (VRD) versus lenalidomide and low‐dose dexamethasone (Ld) for newly‐diagnosed multiple myeloma‐ a randomized phase III study. Blood. 2017;130:906.
    1. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment‐refractory multiple myeloma (SIRIUS): an open‐label, randomised, phase 2 trial. Lancet. 2016;387:1551–60. - PubMed
    1. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol. 2008;141:149–69. - PubMed
    1. Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22:220–9. - PubMed
    1. Sandilya V. Therapeutic plasma exchange (TPE, plasmapheresis) for treatment of refractory autoimmune hemolytic anemia (AIHA). Blood. 2008;112:5380–0.

Publication types